DDR1 and neoplasm: Motivated by compelling evidence of DDR1’s role in shaping immunosuppressive PDAC microenvironments, we therapeutically targeted DDR1 using a novel neutralizing antibody (HYXL-3) to assess blockade efficacy in reversing immune evasion and inhibiting tumor progression.